- Open Access
Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients
Stem Cell Research & Therapy volume 7, Article number: 88 (2016)
The suppressive effect of mesenchymal stromal/stem cells (MSCs) on diverse immune cells is well known, but it is unclear whether MSCs additionally possess immunostimulatory properties. We investigated the impact of human MSCs on the responsiveness of primary natural killer (NK) cells in terms of cytokine secretion.
Human MSCs were generated from bone marrow and nasal mucosa. NK cells were isolated from peripheral blood of healthy volunteers or of immunocompromised patients after severe injury. NK cells were cultured with MSCs or with MSC-derived conditioned media in the absence or presence of IL-12 and IL-18. C-C chemokine receptor (CCR) 2, C-C chemokine ligand (CCL) 2, and the interferon (IFN)-γ receptor was blocked by specific inhibitors or antibodies. The synthesis of IFN-γ and CCL2 was determined.
In the absence of exogenous cytokines, trace amounts of NK cell-derived IFN-γ licensed MSCs for enhanced synthesis of CCL2. In turn, MSCs primed NK cells for increased release of IFN-γ in response to IL-12 and IL-18. Priming of NK cells by MSCs occurred in a cell–cell contact-independent manner and was impaired by inhibition of the CCR2, the receptor of CCL2, on NK cells. CD56bright NK cells expressed higher levels of CCR2 and were more sensitive to CCL2-mediated priming by MSCs and by recombinant CCR2 ligands than cytotoxic CD56dim NK cells. NK cells from severely injured patients were impaired in cytokine-induced IFN-γ synthesis. Co-culture with MSCs or with conditioned media from MSCs and MSC/NK cell co-cultures from healthy donors improved the IFN-γ production of the patients’ NK cells in a CCR2-dependent manner.
A positive feedback loop driven by NK cell-derived IFN-γ and MSC-derived CCL2 increases the inflammatory response of cytokine-stimulated NK cells not only from healthy donors but also from immunocompromised patients. Therapeutic application of MSCs or their soluble factors might thus improve the NK function after severe injury.
Mesenchymal stromal/stem cells (MSCs) are nonhematopoietic, multipotent progenitor cells that may give rise to osteoblasts, chondrocytes, and adipocytes. MSCs are defined according to their lack of the hematopoietic and endothelial markers CD45 and CD34 and their expression of the stromal markers CD105, CD90, CD29, and CD73 . Because of their potential for trilineage differentiation, MSCs are considered to contribute to tissue regeneration . In addition, MSCs release C-C chemokine ligand (CCL) 2 (also known as monocyte-chemoattractant protein MCP-1) that recruits monocytes/macrophages to the site of injury and, thereby, supports wound healing .
MSCs not only possess regenerative capacity but also display immunomodulatory properties. As part of the hematopoietic stem cell niche, MSCs are tightly located to hematopoietic stem cells and are involved in the maintenance of hematopoiesis . Moreover, MSCs regulate the function of finally differentiated immune cells due to the release of regulatory mediators such as prostaglandin E (PGE) 2, interleukin (IL)-10, or transforming growth factor (TGF)-β . MSCs inhibit the proliferation of T cells, the release of inflammatory cytokines by dendritic cells and macrophages, the proliferation and immunoglobulin production of B cells, and the cytotoxic activity of natural killer (NK) cells . This regulatory activity of MSCs has led to the development of novel therapeutic approaches in the treatment of inflammatory disorders such as graft-versus-host disease or autoimmunity. More recently it has been shown that MSCs do not act as immunosuppressant cells by “default” but may also enhance inflammation depending on the microenvironment .
NK cells belong to the innate immune system and can be divided into two subpopulations depending on their expression of the adhesion molecule CD56 . CD56dim NK cells are involved in the defense against virus infections and tumor cells through their cytotoxic activity. In contrast, CD56bright NK cells possess only poor cytotoxic activity but release high amounts of interferon (IFN)-γ upon exposure to the proinflammatory cytokines IL-12 and IL-18, and thereby contribute to effective antimicrobial immune responses . From previous in-vitro studies it is known that MSCs suppress the tumor cell-directed cytotoxicity, proliferation, and IFN-γ secretion of NK cells mainly through the release of PGE2 and the activity of indoleamine 2,3-dioxygenase (IDO) . In contrast to these reports, we have recently shown that MSCs enhance the release of IFN-γ from a NK cell line in the context of stimulation with IL-12 and IL-18. The stimulatory effect of MSCs on the NK cells occurs in a cell–cell contact-dependent and contact-independent manner and is associated with an increased expression of the IL-12 receptor on NK cells .
In the present study, we investigated the underlying mechanism of MSC-mediated NK cell stimulation. We identified a novel positive feedback loop between MSCs and primary human NK cells including the release of CCL2/MCP-1 by MSCs and IFN-γ by NK cells. The stimulatory activity of MSCs largely affected the CD56bright NK cell subpopulation. Moreover, MSCs improved the function of NK cells from severely injured patients who are at enhanced risk for nosocomial infections due to the development of immunosuppression .
Bone marrow aspirate was obtained from patients who underwent total hip replacement surgery. Peripheral blood was drawn from healthy donors and from severely injured patients on day 8 after injury. The patients were at least 18 years old, suffered multiple injuries such as thorax trauma, bone fracture, hemorrhage, brain injury, or soft tissue trauma, and displayed an Injury Severity Score (ISS) > 16 (Table 1). Informed consent was obtained from volunteers and from patients or their legal representatives (in case of unconsciousness). The study was performed according to the Declaration of Helsinki and was approved by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen.
Generation of MSCs
Mononuclear cells from bone marrow aspirates were isolated by density gradient centrifugation using Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany) according to the manufacturer’s protocol. After washing with Dulbecco’s Phosphate Buffer Saline (DPBS; Gibco Life Technologies, Darmstadt, Germany) the cell pellet was resuspended in “MSC-medium” composed of Dulbecco’s modified Eagle’s medium (DMEM; Gibco Life Technologies) supplemented with 10 % endotoxin-tested fetal calf serum (FCS; Biochrome, Berlin, Germany), 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM l-glutamax, and 1 mM sodium pyruvate (all from Sigma, Deisenhofen, Germany). One million mononuclear cells were seeded in 7 ml MSC-medium per T75 cm2 flask (Greiner Bio-One) and were incubated in a humidified atmosphere containing 5 % CO2 at 37 °C. After 24 h, half of the medium was replaced by fresh MSC-medium. Forty hours later, the nonadherent cells were removed by gentle washing with phosphate-buffered saline (PBS; Gibco Life Technologies) before addition of MSC-medium. Thereafter, the medium was replaced twice a week. When the cells reached a confluency of around 80 % they were detached using 6 ml Accutase (Gibco Life Technologies), harvested, and reseeded at 106 cells per flask (T75 cm2) in 7 ml MSC-medium. After three passages, phenotypical characterization was performed by flow cytometry . All MSCs were negative for the hematopoietic or endothelial markers CD45, CD34, and CD31 but expressed the characteristic MSC markers CD29, CD73, CD90, and CD105 (see Additional file 1: Figure S1). MSCs were used in passages 3–8 throughout the experiments. MSCs from nasal mucosa (nmMSCs) were generated as described previously . MSCs from five bone marrow aspirate donors and from three nasal mucosa donors were used in this study.
Isolation of mononuclear cells and NK cells from blood
Peripheral blood mononuclear cells (PBMC) were obtained from peripheral blood density gradient centrifugation as already described. Untouched NK cells were isolated from PBMC using a negative selection human NK cell isolation kit with AutoMACS (both from Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instruction. The purity of CD56+ NK cells was >90 % as determined by flow cytometry. NK cells were cultured in “NK cell-medium” Very Low Endotoxin medium VLE RPMI-1640 (Biochrome) supplemented with 10 % FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM l-glutamax (all from Sigma). Purified NK cells were directly used for the experiments. NK cells from 27 healthy donors and from six patients were used in this study.
MSCs were seeded at 1.25 × 104 cells per well (24-well plate; BD Biosciences, Heidelberg, Germany) in 900 μl MSC-medium. The medium was aspirated after overnight culture and 6.25 × 104 NK cells in 900 μl NK cell-medium were added. As controls, MSCs and NK cells were cultured alone in NK cell-medium. In parallel, cell-free NK cell-medium was incubated under identical conditions. In one experimental set-up, NK cells were placed in a 24-well trans-well plate (0.4 μm pore size; BD Biosciences) with MSCs on the bottom of the culture plate. After 24 h, the cultures underwent one of the following three procedures: “co-culture”, NK cell mono-cultures and MSC/NK cell co-cultures were stimulated with IL-12 (1 ng/ml; Miltenyi Biotec) and IL-18 (10 ng/ml; MBL International, Woburn, MA, USA); “detachment”, NK cells from mono-cultures and NK cells that were detached from MSCS in the co-cultures were harvested by gentle pipetting, washed, and replated in fresh wells (1 × 104 NK cells/well, 96-well plate; BD Biosciences) before stimulation with IL-12 (1 ng/ml) and IL-18 (10 ng/ml); and “conditioned media”, supernatants from MSCs alone, NK cells alone, MSC/NK cell-co-cultures, and the cell-free medium were harvested and served as “conditioned media” after removal of residual cells by centrifugation. The conditioned media (150 μl) were immediately transferred to freshly isolated NK cells that were seeded at 1 × 104 per well (96-well plate) in 50 μl NK cell-medium. Thereafter, the cells were stimulated with IL-12 (1 ng/ml) and IL-18 (10 ng/ml) or left unstimulated as a negative control.
Alternatively, freshly isolated NK cells (1 × 104 per well; 96-well plate) were cultured in the presence or absence of recombinant human CCL2/MCP-1, CCL8, CCL7, or CCL12 (all from PeproTech, Hamburg, Germany) at a final concentration of 0.5 ng/ml for 12 h before stimulation with IL-12 (1 ng/ml) and IL-18 (5 ng/ml).
Where specified, neutralizing monoclonal antibodies against CCL2/MCP-1 (clone 2H5; BioXCell, West Lebanon, NH, USA), unspecific hamster IgG isotype control antibodies (each 10 μg/ml; BioXCell), inhibitory monoclonal antibodies against the IFN-γ receptor 1 (clone GIR208; Biotechne, Wiesbaden, Germany), unspecific mouse IgG1 isotype control antibodies (each 10 μg/ml; Biotechne), a selective antagonist of the C-C-chemokine receptor (CCR) 2 (RS102895, 5 nM; Tocris Bioscience, Bristol, UK), or dimethyl sulfoxide (DMSO; Sigma) as solvent control were added to the cultures. In general, all cultures were set up in 4–5 replicates. Cell supernatants were harvested 24 h after stimulation with IL-12 and IL-18 and were stored at –20 °C.
In a separate set of experiments, MSCs were seeded as already described and treated with different concentrations of recombinant human IFN-γ (5–100 pg/ml; Miltenyi Biotec) or with PBS as control for 12 h before supernatants were harvested.
Quantification of CCL2/MCP-1 and IFN-γ
Quantification of human CCL2/MCP-1 and IFN-γ was performed by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (DuoSet; Biotechne). The detection limit was 15 pg/ml. For some analyses, a specialized highly sensitive IFN-γ ELISA with a detection limit of 1.6 pg/ml was used according to the manufacturer’s instructions (NBP1-91174 Interferon gamma; Novus Biologics/Biotechne).
PBMC were incubated with fluorescent antibodies against CD3 (fluorescein isothiocyanate-labeled, clone DaA3; Immuno Tools, Friesoythe, Germany), CD56 (allophycocyanin-labeled, clone CMSSB; eBioscience, San Diego, CA, USA), and CD192/CCR2 (phycoerythrin-labeled, clone K036C2; Biolegend, San Diego, CA, USA) for 12 min at 4 °C. Thereafter, the cells were washed with Cell Wash (BD Biosciences).
For intracellular detection of IFN-γ in NK cells, 0.5 μl/ml of Golgi-Stop (Monensin; BD Biosciences) was added during the last 5 h of culture. After surface staining using anti-CD3 and anti-CD56 antibodies as already described, the cells were fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences) and antibodies against IFN-γ (phycoerythrin-labeled, clone 4S.B3; Biolegend) were added. After 20 min, the cells were washed.
Appropriate isotype controls were used for all stainings. The acquisition of data was performed using FACSCalibur (BD Biosciences). Data were analyzed using Cell Quest Pro software (BD Biosciences). NK cells were identified and gated as CD3–CD56bright or CD3–CD56dim cells. The expression of CCR2 and IFN-γ on/in gated NK cells was quantified according to the isotype control staining.
Data from replicate cultures are presented as mean ± SD in bar graphs and statistical analysis was performed using one-way ANOVA followed by the Bonferroni multiple comparison test. Combined data of multiple donors are presented as scatter plots and median with interquartile range. Statistical analysis was performed using the Mann–Whitney U test or Wilcoxon signed-rank test as indicated. GraphPad Prism 5.0 served as the software for the analyses. p ≤ 0.05 was considered statistically significant.
MSCs prime NK cells for increased IFN-γ secretion
We have previously shown that human bone marrow-derived MSCs prime NK-92 cells, a human NK cell line, for increased release of IFN-γ upon stimulation with IL-12 and IL-18. We investigated whether MSCs similarly modulated human primary NK cells from peripheral blood and whether the presence of MSCs during stimulation of NK cells with cytokines was required to exert their stimulatory effect on NK cells. Therefore, human primary NK cells were isolated from peripheral blood of healthy donors and were cultured alone or together with MSCs at a ratio of 5:1 (NK cells:MSCs) for 24 h before stimulation with IL-12 and IL-18. At this ratio MSCs displayed an intermediate stimulatory effect on NK cells as verified previously . Unstimulated cells served as negative controls. In the absence of IL-12 and IL-18, NK cells did not release detectable levels of IFN-γ (Fig. 1a). As expected, NK cells released IFN-γ after exposure to IL-12 and IL-18. In the presence of MSCs, IFN-γ secretion by NK cells increased by 2-fold (Fig. 1a).
To address the relevance of MSCs during stimulation of NK cells, mono-cultures and co-cultures were set up. After 24 h, NK cells were carefully harvested, washed, and transferred into fresh culture plates before stimulation. NK cells that had been co-cultured with MSCs and then separated released significantly higher levels of IFN-γ than NK cells that had been cultured alone (Fig. 1b). No IFN-γ was released from reseeded NK cells in the absence of IL-12 and IL-18 (Fig. 1b).
Because contact with MSCs during stimulation of NK cells with IL-12 and IL-18 was not required to increase the release of IFN-γ, we next investigated whether soluble factor(s) derived from MSCs were responsible for the priming effect on NK cells. Therefore, “conditioned media” from NK cells alone, MSCs alone, and MSC/NK cell co-cultures were harvested and transferred to freshly isolated NK cells. Transfer of cell-free medium that had been kept under identical conditions to the cells was used as control. Thereafter, the NK cells were stimulated or left unstimulated. In the presence of conditioned medium from MSCs alone and, even more, from MSC/NK cell co-cultures, NK cells released significantly increased amounts of IFN-γ upon stimulation (Fig. 1c). The conditioned medium from NK cell mono-cultures did not change the IFN-γ production (Fig. 1c). Conditioned media did not induce the secretion of IFN-γ from NK cells in the absence of IL-12 and IL-18 (Fig. 1c).
Intracellular staining and flow cytometry revealed that CD56bright NK cells were the main subpopulation that secreted IFN-γ upon stimulation (Fig. 1d). Thus, MSCs instruct primary NK cells for increased IL-12/IL-18-induced IFN-γ secretion through a soluble factor.
MSC-derived CCL2/MCP-1 mediates NK cell priming
We determined the content of CCL2/MCP-1 in the conditioned media from mono-cultures and co-cultures that had been prepared as already described. No CCL2/MCP-1 was detectable in the supernatant from NK cells. As expected, MSCs alone released CCL2/MCP-1 (Fig. 2a). When co-cultured with NK cells, MSCs released more CCL2/MCP-1 (Fig. 2a). The extent of CCL2 secretion varied depending on the combination of MSCs and NK cells (Fig. 2b). To evaluate whether CCL2/MCP-1 might contribute to the MSC-mediated priming of NK cells for increased IFN-γ synthesis, we first investigated whether NK cells expressed CCR2, the receptor for CCL2/MCP-1. CD56bright NK cells expressed CCR2 at much higher levels than CD56dim NK cells (Fig. 2c). We observed a large variation in CCR2 expression between different donors (Fig. 2d).
Next, we investigated the priming of NK cells by MSCs in the presence of neutralizing antibodies against CCL2/MCP-1. Mono-cultures and co-cultures were therefore set up in the presence or absence of neutralizing antibodies against CCL2/MCP-1 before stimulation. Neutralization of CCL2/MCP-1 reduced the secretion of IFN-γ in MSC/NK cell co-cultures but not in cultures of NK cells alone (Fig. 3a, b). In the absence of IL-12 and IL-18, NK cells did not secrete detectable levels of IFN-γ (data not shown).
We asked whether CCL2/MCP-1 likewise contributed to the stimulatory activity of the conditioned media when transferred to fresh NK cells. Neutralization of CCL2/MCP-1 completely and partially abrogated the stimulatory effect of the conditioned media from MSCs and from MSC/NK cell co-cultures, respectively (Fig. 3c, d).
Likewise, inhibition of CCR2, the receptor for CCL2, with the specific inhibitor RS102895 clearly decreased the release of IFN-γ from NK cells when co-cultured together with MSCs but not when cultured alone (Fig. 4a, b). Moreover, inhibition of CCR2 completely reversed the stimulatory effect of the conditioned medium from MSCs on the NK cell-derived IFN-γ production and clearly decreased the priming that was mediated by conditioned medium from MSC/NK cell co-cultures (Fig. 4c, d). In the absence of IL-12 and IL-18, NK cells did not secrete detectable levels of IFN-γ (data not shown).
In order to investigate whether the NK cell-stimulatory activity was specific for bone marrow-derived MSCs we additionally used nmMSCs in the same experimental set-up. Upon contact with NK cells, nmMSCs strongly increased their release of CCL2 (Fig. 4e). In turn, the contact with nmMSCs stimulated NK cells for enhanced IL-12/IL-18-induced secretion of IFN-γ in a CCR2-dependent manner (Fig. 4f).
Having established that CCR2 and its ligand CCL2/MCP-1 contributed to the MSC-mediated priming of NK cells, we asked whether targeting CCR2 was a general mechanism that stimulates NK cells for enhanced release of IFN-γ. In addition to CCL2/MCP-1 there exist several ligands of CCR2, namely CCL8/MCP-2, CCL7/MCP-3, and CCL12/MCP-5. NK cells were therefore cultured in the presence or absence of diverse CCR2 ligands before stimulation at suboptimal levels in order to detect the synergism between the recombinant chemokines and IL-12/IL-18. As control, NK cells were treated with the CCR2 ligands alone. All ligands increased the IL-12/IL-18-induced release of IFN-γ (Fig. 5a). None of the ligands induced the release of IFN-γ in the absence of IL-12 and IL-18 (Fig. 5a). Intracellular staining revealed that the CCR2 ligands similar to conditioned medium from MSCs increased the percentage of IFN-γ-producing CD56bright NK cells upon exposure to IL-12 and IL-18 (Fig. 5b, c). In contrast, CD56dim NK cells did not respond to the CCR2 ligands or to the conditioned medium (Additional file 2: Figure S2). Thus, CCL2/MCP-1 is released by MSCs and MSC/NK cell co-cultures and stimulates CD56bright NK cells for increased IL-12/IL-18-induced IFN-γ synthesis in a CCR2-dependent manner.
NK cell-derived IFN-γ licenses MSCs for increased CCL2/MCP-1 release
Considering that MSCs released enhanced amounts of CCL2/MCP-1 when cultured in the presence of NK cells under neutral conditions (Fig. 2a) we asked whether NK cells in turn stimulated MSCs through IFN-γ. Therefore, mono-cultures and co-cultures were set up in the presence of antibodies that blocked the IFN-γ receptor. No further cytokines were added. Moreover, co-cultures were set up in a trans-well system that allows the exchange of soluble factors but prevents direct cell-to-cell contact. The content of IFN-γ was determined using a highly sensitive ELISA. No IFN-γ was detected in supernatants from MSCs alone (Fig. 6a). IFN-γ was present at very low levels in MSC/NK cell co-cultures independent of the cell contact (Fig. 6a). Blocking of the IFN-γ receptor led to the accumulation of IFN-γ in all MSC/NK cell co-cultures but not in MSC mono-cultures (Fig. 6a). Quantification of CCL2/MCP-1 in the same supernatants revealed that the constitutive release of CCL2/MCP-1 by MSCs was not affected by blocking the IFN-γ receptor. In contrast, the increased synthesis of CCL2/MCP-1 in the MSC/NK cell co-cultures was completely abrogated in the presence of the anti-IFN-γ receptor antibodies (Fig. 6b). The separation of MSCs and NK cells during culture did not change the NK cell-mediated increase of CCL2/MCP-1 production or the suppressive effect of the anti-IFN-γ receptor antibodies on the synthesis of CCL2/MCP-1 (Fig. 6b).
To confirm that such a low amount of IFN-γ as found in the MSC/NK cell co-cultures was able to increase the release of MSC-derived CCL2/MCP-1, MSCs were cultured with low concentrations of recombinant IFN-γ. We observed that as little as 5 pg/ml IFN-γ was sufficient to significantly increase the release of CCL2/MCP-1 by MSCs (Fig. 6c). Thus, under neutral conditions NK cell-derived IFN-γ licenses MSCs for increased CCL2/MCP-1 production.
MSC-derived CCL2/MCP-1 improves the function of NK cells of immunocompromised patients
Next, we asked whether MSCs exert their stimulatory capacity not only under physiological conditions but also under pathological conditions that are associated with suppressed NK cell function. We have evidence that NK cells from critically ill patients after major injury and surgery are impaired in function [14, 15]. In a small pilot study, we investigated the IFN-γ release from NK cells isolated from patients after severe injury and evaluated whether it was modulated by MSCs from healthy individuals. NK cells from critically ill patients and from healthy donors (for characteristics see Table 1) were therefore stimulated with IL-12 and IL-18. NK cells from patients released much less IFN-γ than NK cells from control subjects (Fig. 7a). The synthesis of IFN-γ was increased when the patients’ NK cells were cultured together with MSCs (Fig. 7b, c). The stimulatory effect of MSCs on these NK cells was partially inhibited by neutralization of CCL2/MCP-1 (Fig. 7b, c).
Moreover, the stimulatory effect of conditioned media from cells of healthy donors on NK cells from severely injured patients was evaluated. Conditioned medium from MSCs and from MSC/NK cell co-cultures of healthy donors increased the IL-12/IL-18-induced IFN-γ secretion from the patients’ NK cells in a CCL2/MCP-1-dependent manner (Fig. 7d). Overall, the stimulatory activity of conditioned media from MSCs and MSC/NK co-cultures on the patients’ NK cells was 2-fold and 3.3-fold, respectively (Fig. 7e). In the absence of IL-12 and IL-18, the patients’ NK cells did not release detectable levels of IFN-γ (data not shown). The CCL2/MCP-1-mediated activity of MSCs is thus not restricted to NK cells under homeostasis but also seems to be applicable to NK cells that are suppressed in function due to critical illness.
The majority of studies on the immunomodulatory activity of MSCs report the inhibitory effect of MSCs on diverse cells of the immune system. The key factors in human MSC-mediated immunoregulation are IDO, PGE2, and TGF-β . There exist only few reports on proinflammatory properties of MSCs that deal with the attraction and stimulation of granulocytes or macrophages [16, 17]. We have previously identified another proinflammatory activity of MSCs because they increase the production of IL-12 and IL-18-induced IFN-γ from NK-92 cells through unknown mechanisms . We show here that MSCs exerted their stimulatory activity also on human primary NK cells during cell–cell contact as well as through a soluble factor. In line with previous reports, the minor CD56bright NK cell population was superior in IL-12/IL-18-induced IFN-γ production compared with the CD56dim NK cell subtype . Accordingly, the MSC-mediated stimulation of NK cells was more apparent in CD56bright NK cells. Overall, we observed a broad range of the amount of CCL2 and IFN-γ that was released from MSCs and NK cells from different donors, respectively. A donor-dependent variation of the size of the CD56bright NK cell population among total NK cells might contribute to the diverse IFN-γ production of the NK cells. The finding that conditioned medium from MSC/NK cell co-cultures was more potent in NK cell stimulation than conditioned medium from MSCs alone indicates that an immunostimulatory factor was released during the interaction of MSCs and NK cells.
Mechanistically, we identified chemokine receptor CCR2 and its ligand CCL2/MCP-1 as the major components in the MSC-mediated stimulation of NK cells. MSCs constitutively secrete CCL2/MCP-1 and other chemokines . CCR2, the receptor for CCL2/MCP-1, is expressed on diverse immune cells, such as monocytes/macrophages, dendritic cells, T cells, and NK cells. CCL2/MCP-1 so far seemed to contribute to the immunosuppressive properties of MSCs. MSC-derived CCL2/MCP-1 attracts macrophages to tumors and thereby promotes tumor growth . Likewise, murine T cells are recruited by MSC-derived CCL2/MCP-1 and subsequently are suppressed by NO that is released into the microenvironment by murine MSCs . In addition to its chemotactic activity, MSC-derived CCL2/MCP-1 directly modulates cellular functions of target cells, such as the immunoglobulin production by plasma cells and the inhibition of Th17 T cells [22, 23].
In line with a previous study we observed that CD56bright NK cells displayed a stronger expression of the CCR2 than CD56dim NK cells . The knowledge on the impact of CCL2/MCP-1 on NK cells is largely restricted to its chemotactic properties [24, 25]. We provide the novel finding that MSC-derived CCL2/MCP-1 directly acts on resting CD56bright NK cells that subsequently respond to IL-12 and IL-18 with an increased production of IFN-γ. The weak expression of the CCR2 on CD56dim NK cells might explain why MSCs do not promote but rather reduce the low production of IFN-γ from CD56dim NK cells when examined immediately after stimulation . The finding that blocking of CCL2/MCP-1 in conditioned media from MSCs/NK cell co-cultures was less effective than inhibition of the CCR2 on NK cells led to the assumption that CCL2/MCP-1 was not the only factor which triggered CCR2 on CD56bright NK cells. Indeed, alternative ligands of CCR2—namely CCL7, CCL8, and CCL12—displayed similar stimulatory activity on CD56bright NK cells and might also have been present in the conditioned media from MSCs.
It remains unclear how CCL2/MCP-1-mediated signaling interacts with the IL-12/IL-18-induced pathway in CD56bright NK cells. Activation of suppressor of cytokine signaling 3 (SOCS3) and suppression of T-box expressed in T cells (T-bet) were identified as mechanistic targets of CCL2 secreted from decidual stromal cells on diverse leukocytes [19, 27]. However, transcription of the ifng gene requires the expression of T-bet and is suppressed by SOCS3 [28–30]. Therefore, we assume that signaling pathways distinct to activation of SOCS3 and suppression of T-bet are induced in CD56bright NK cells after exposure to MSC-derived CCL2 in order to increase their IFN-γ response.
Several studies in the past have shown that MSCs require licensing by exogenously added IFN-γ and tumor necrosis factor alpha or by specific toll-like receptor ligands to acquire immunosuppressive effects [31–34]. In our study, the interaction of MSCs and NK cells occurred in the absence of exogenous proinflammatory or anti-inflammatory factors. Minute amounts of IFN-γ that were produced in the MSC/NK cell co-cultures were sufficient to further drive the release of CCL2/MCP-1 from MSCs, indicating that NK cells licensed MSCs in the neutral environment. On the contrary, the bidirectional interaction with MSCs primed NK cells in a CCR2-dependent manner for increased IFN-γ secretion upon exposure to IL-12 and IL-18. This immunostimulatory feedback loop between MSCs and NK cells represents a novel aspect in the plasticity of MSC function.
NK cells maintained their enhanced responsiveness to IL-12 and IL-18 even after detachment from MSCs and removal of MSC-derived factors. This is in contrast to the well-studied MSC-mediated suppression of T-cell responsiveness that requires a closer vicinity between MSCs and T cells as the immunosuppressive factors NO and IDO act only over a short distance [21, 35]. Transferred to a potential in-vivo situation, we speculate that, after priming by MSCs, CD56bright NK cells may support inflammation both locally and distant to the site of MSC encounter; for example, upon infection that is associated with the release of IL-12 and IL-18 [36, 37]. It is important to note that MSC-derived CCL2/MCP-1 per se did not induce the release of IFN-γ from NK cells. Thus, it is unlikely that MSCs cause uncontrolled inflammation in the absence of, for example, an infectious insult. Moreover, considering the importance of NK cell-derived IFN-γ in T-helper cell polarization in lymphoid organs, such MSC-primed NK cells might favor the development of inflammatory T-helper cell type 1 responses . Further studies are required to evaluate the existence and the consequences of MSC-mediated NK cell priming in vivo, especially under the view of the growing number of clinical studies based on the therapeutic application of MSCs.
The administration of anti-inflammatory MSCs in clinical trials has so far been aimed largely at treating hyperinflammatory diseases such as graft-versus-host disease and autoimmunity [39, 40]. Because of their inhibitory properties the use of MSCs in diseases associated with immunodeficiency has so far been regarded as contraindicative. Severe injuries or invasive surgical interventions cause a state of immunosuppression . These patients suffer from nosocomial infections that may result in life-threatening septic shock. The underlying pathomechanisms of injury-induced immunosuppression are not yet fully understood and protective therapies are warranted. We have presented evidence that NK cells from severely injured patients are impaired in IFN-γ production upon exposure to Staphylococcus aureus . In line with these data, we show here for the first time that NK cells from severely injured patients are suppressed in their capacity to secrete IFN-γ in response to IL-12/IL-18, the key cytokines in the defense against diverse pathogens. We observed that MSCs from healthy donors at least partially restored the suppressed IFN-γ synthesis of NK cells from such patients. Moreover, conditioned media from MSCs as well as from co-cultures of MSCs and NK cells from healthy donors clearly improved the IFN-γ release from NK cells of injured patients. Similar to our data obtained from NK cells from healthy donors, CCL2/MCP-1 mediated the stimulatory effect of MSCs and their conditioned media on the patients’ NK cells.
In the neutral environment, trace amounts of NK cell-derived IFN-γ licensed MSCs for enhanced release of CCL2/MCP-1 that primed NK cells for increased secretion of IFN-γ upon exposure to IL-12 and IL-18. This novel positive feedback loop between MSCs and NK cells was not only observed for NK cells from healthy donors but also for NK cells from immunocompromised patients. Targeting MSCs or their soluble factors to the patients’ NK cells might improve the immune function after severe injury and, thereby, extend the indication of MSC therapy.
CCL, C-C chemokine ligand; CCR, C-C-chemokine receptor; ELISA, enzyme-linked immunosorbent assay; FCS, fetal calf serum; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; IL, interleukin; MCP-1, monocyte-chemoattractant protein; MSC, mesenchymal stromal/stem cell; NK, natural killer; nmMSC, mesenchymal stromal/stem cell from nasal mucosa; PBMC, peripheral blood mononuclear cells; PGE, prostaglandin E; SOCS3, suppressor of cytokine signaling 3; T-bet, T-box expressed in T cells; TGF, transforming growth factor
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7.
Yousefi AM, James PF, Akbarzadeh R, Subramanian A, Flavin C, Oudadesse H. Prospect of stem cells in bone tissue engineering: a review. Stem Cells Int. 2016;2016:6180487.
Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008;3:e1886.
Schepers K, Campbell TB, Passegue E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16:254–67.
Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012;33:136–43.
English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2013;91:19–26.
Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392–402.
Caligiuri MA. Human natural killer cells. Blood. 2008;112:461–9.
Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol. 2006;18:391–8.
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111:1327–33.
Thomas H, Jäger M, Mauel K, Brandau S, Lask S, Flohé SB. Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators Inflamm. 2014;2014:143463.
Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40:793–808.
Jakob M, Hemeda H, Janeschik S, Bootz F, Rotter N, Lang S, et al. Human nasal mucosa contains tissue-resident immunologically responsive mesenchymal stromal cells. Stem Cells Dev. 2010;19:635–44.
Kleinertz H, Reinhardt R, Waydhas C, Flohé S, Leenen M, Flohé SB. CD56hi NK cells as novel players in immunosuppression after polytrauma: impaired responsiveness to IL-12 causes deficits in the response to Staphylococcus aureus. Shock. 2015;44 Suppl 2:23.
Reinhardt R, Pohlmann S, Kleinertz H, Hepner-Schefczyk M, Paul A, Flohé SB. Invasive surgery impairs the regulatory function of human CD56bright natural killer cells in response to Staphylococcus aureus. Suppression of interferon-gamma synthesis. PLoS One. 2015;10:e0130155.
Brandau S, Jakob M, Bruderek K, Bootz F, Giebel B, Radtke S, et al. Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS One. 2014;9:e106903.
Evans JF, Salvador V, George S, Trevino-Gutierrez C, Nunez C. Mouse aorta-derived mesenchymal progenitor cells contribute to and enhance the immune response of macrophage cells under inflammatory conditions. Stem Cell Res Ther. 2015;6:56.
Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458–65.
Xu X, Wang Q, Deng B, Wang H, Dong Z, Qu X, et al. Monocyte chemoattractant protein-1 secreted by decidual stromal cells inhibits NK cells cytotoxicity by up-regulating expression of SOCS3. PLoS One. 2012;7:e41869.
Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell. 2012;11:812–24.
Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141–50.
Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008;112:4991–8.
Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009;182:5994–6002.
Morandi F, Ferretti E, Castriconi R, Dondero A, Petretto A, Bottino C, et al. Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood. 2011;118:5840–50.
Maghazachi AA, Al-Aoukaty A, Schall TJ. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J Immunol. 1994;153:4969–77.
Chatterjee D, Marquardt N, Tufa DM, Hatlapatka T, Hass R, Kasper C, et al. Human umbilical cord-derived mesenchymal stem cells utilize activin-A to suppress interferon-gamma production by natural killer cells. Front Immunol. 2014;5:662.
He YY, He XJ, Guo PF, Du MR, Shao J, Li MQ, et al. The decidual stromal cells-secreted CCL2 induces and maintains decidual leukocytes into Th2 bias in human early pregnancy. Clin Immunol. 2012;145:161–73.
Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 2006;24:575–90.
Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham PJ, Biron CA, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity. 2004;20:477–94.
Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun. 2003;310:1188–93.
DelaRosa O, Lombardo E, Beraza A, Mancheno-Corvo P, Ramirez C, Menta R, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A. 2009;15:2795–806.
Zhao X, Liu D, Gong W, Zhao G, Liu L, Yang L, et al. The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells. 2014;32:521–33.
Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 2009;27:909–19.
Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–98.
Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762–74.
Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000;12:59–63.
Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol. 1998;16:365–96.
Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5:1260–5.
Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 2010;59:1662–9.
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.
The authors thank all volunteers and patients for their donation of blood.
Availability of data and materials
The datasets supporting the conclusions of this article are included within the article and its additional files.
RC was responsible for collection and assembly of data, data analysis and interpretation, and manuscript writing. HR, MH-S, KF, and RMP were responsible for collection of data and manuscript writing. KB was responsible for collection and assembly of data, data analysis, and manuscript writing. SB was responsible for collection of data, data interpretation, and manuscript writing. MJ was responsible for provision of study material and manuscript writing. SBF was responsible for conception and design, manuscript writing, final approval of manuscript, assembly of data, and data analysis and interpretation. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Informed consent was obtained from volunteers and from patients or their legal representatives (in case of unconsciousness). The study was performed according to the declaration of Helsinki and was approved by the Ethics Committee of the medical faculty of the University Duisburg-Essen.
Expression of specific molecules on MSCs. MSCs were incubated with fluorochrome-labeled antibodies against CD45, CD31, CD34, CD73, CD105, CD29, and CD90, and with the respective isotype control antibodies. Representative histograms show the fluorescence of the isotype (grey shaded area) and the specific antibody (black line). MSC mesenchymal stromal/stem cell (PDF 48 kb)
CD56dim NK cells do not respond to CCR2 ligands. NK cells were incubated in the absence (–) or presence of 0.5 ng/ml of recombinant human CCL2, CCL8, CCL7, and CCL12, or with conditioned medium (CM) from MSCs for 12 h. Thereafter, the cells were stimulated with IL-12 (1 ng/ml) and IL-18 (5 ng/ml). Dot plots of intracellular staining of IFN-γ in gated CD3–CD56dim NK cells (gating strategy as shown in Fig. 1d). Data are representative for one out of five experiments. The threshold of positive staining for IFN-γ was set according to the isotype control (iso). Numbers indicate the percentage of IFN-γ-positive NK cells. MSC mesenchymal stromal/stem cell, CCL C-C ligand, IFN interferon. (PDF 36 kb)
About this article
Cite this article
Cui, R., Rekasi, H., Hepner-Schefczyk, M. et al. Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Stem Cell Res Ther 7, 88 (2016). https://doi.org/10.1186/s13287-016-0353-9
- Mesenchymal stromal cells
- Mesenchymal stem cells
- Natural killer cells
- Interferon gamma